UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Millions	Jun. 30, 2022	Dec. 31, 2021
Current assets:
Cash and cash equivalents	$ 723.0	$ 1,068.2
Short-term investments	0.0	100.0
Accounts receivable, net	402.6	416.9
Inventories	759.0	710.1
Assets held for sale	0.0	4.4
Other current assets	202.9	172.2
Total current assets	2,087.5	2,471.8
Property, plant and equipment, net	395.0	406.1
Goodwill	396.2	339.5
Intangible assets, net	233.5	211.8
Other long-term assets	272.6	220.8
Total assets	3,384.8	3,650.0
Current liabilities:
Current portion of long-term debt	14.0	112.4
Accounts payable	154.9	147.4
Customer advances	196.7	197.5
Other current liabilities	452.8	481.2
Total current liabilities	818.4	938.5
Long-term debt	1,171.0	1,221.8
Other long-term liabilities	404.7	404.9
Commitments and contingencies (Note 14)
Redeemable noncontrolling interests	6.3	0.2
Shareholders' equity:
Preferred stock, $0.01 par value 5,000,000 shares authorized, none issued or outstanding	0.0	0.0
Common stock, $0.01 par value 260,000,000 shares authorized, 175,062,026 and174,905,035 shares issued and 148,323,882 and 150,753,687 shares outstanding at June 30, 2022 and December 31, 2021, respectively	1.7	1.7
Treasury stock, at cost, 26,738,144 and 24,151,348 shares at June 30, 2022 and December 31, 2021, respectively	(986.2)	(820.3)
Accumulated other comprehensive loss, net of tax	(49.3)	(8.2)
Other shareholders' equity	2,004.3	1,897.3
Total shareholders' equity attributable to Bruker Corporation	970.5	1,070.5
Noncontrolling interests in consolidated subsidiaries	13.9	14.1
Total shareholders' equity	984.4	1,084.6
Total liabilities, redeemable noncontrolling interests and shareholders' equity	$ 3,384.8	$ 3,650.0